retatrutide phase 2 trial Great news again!!! A of (Triple–Hormone-Receptor Agonist) for obesity. At 48 wks the median body weight loss was 24.2% and >5%, >10% and >15% had occurred in 100% Weight loss with retatrutide as
Description
Ready to Take the First Step
Both guidelines agree on whole foods, fewer sugary drinks, and lower sodium, but diabetes care requires individualized application, not one-size-fits-all rules
Common side effects include nausea, vomiting, diarrhea, and constipation, typically mild and temporary
For the liraglutide group participants were started on: 2 metformin, 2 empagliflozin, 1 canagliflozin, 1 semaglutide
